This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Impax (IPXL) Up 35.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Impax (IPXL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Falling Earnings Estimates Signal Weakness Ahead for Impax Laboratories (IPXL)
by Zacks Equity Research
Impax Laboratories (IPXL) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
New Strong Sell Stocks for March 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Impax (IPXL) Q4 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
Impax Laboratories Inc. (IPXL) posted fourth-quarter 2016 adjusted earnings of 16 cents per share, in line with the Zacks Consensus Estimate.
Impax Laboratories (IPXL) is Oversold: Can It Recover?
by Zacks Equity Research
Impax Laboratories, Inc. (IPXL) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Add These 5 Stocks with Low P/B Ratio to Your Portfolio
by Zacks Equity Research
P/B ratio = market capitalization/book value of equity
7 Low Price-to-Cash-Flow Stocks for Assured Returns
by Zacks Equity Research
Investors always try to hit the jackpot while picking stocks. But striking the right chord each time is not easy unless you know the trick.
Cymabay Therapeutics (CBAY) Rises: Stock Moves 9.2% Higher
by Zacks Equity Research
Cymabay Therapeutics, Inc. (CBAY) shares rose over 9% in the last trading session.
5 Value Stocks to Pick Using Price-to-Book Ratio
by Zacks Equity Research
P/B ratio = market capitalization/book value of equity
Zacks.com featured highlights: General Motors, Citizens Financial Group, Impax Laboratories and Cosan
by Zacks Equity Research
Zacks.com featured highlights: General Motors, Citizens Financial Group, Impax Laboratories and Cosan
4 Low P/CF Stocks to Add More Value to Your Investment
by Zacks Equity Research
Value style is considered one of the best practices when it comes to picking stocks.
5 Affordable Stocks with Impressive Returns
by Zacks Equity Research
5 Affordable Stocks with Impressive Returns
Is Impax a Great Stock for Value Investors?
by Zacks Equity Research
Value Investors might consider Impax Laboratories (IPXL) as a great pick on the back of its key value statistics.
Assembly Biosciences (ASMB) Looks Good: Stock Up 13.9%
by Zacks Equity Research
Assembly Biosciences, Inc. (ASMB) was a big mover last session, as the company saw its shares rise nearly 14% on the day.
Stock Market Roundup, Jan. 12: AMZN Jobs, FCAU Cheating, AKS & X Tank
by Ryan McQueeney
As investors continued to worry about President-elect Trump's targeting of the pharma industry, new concerns about U.S. industrial stocks help drag the markets down in morning trading Thursday. Nevertheless, stocks bounced back thanks to overall bullish optimism, and the markets ended on a strong afternoon run that saw indexes down just marginally on the day.
CVS Debuts Cheap EpiPen Alternative
by Madeleine Johnson
On Thursday, leading drug store chain CVS Health Corp. (CVS) announced that it is now selling a cheaper alternative to Mylan's (MYL) EpiPen.
Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases
by Zacks Equity Research
Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.
Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit
by Zacks Equity Research
Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.
Mylan (MYL) Launches Authorized Generic EpiPen at $300
by Zacks Equity Research
Mylan (MYL) announced the launch of the first generic version of its life-saving allergy treatment, EpiPen, at more than 50% discount to the branded product.
20 States Sue Teva, Mylan & Other Drug Companies for Price Fixing
by Arpita Dutt
The lawsuit and the DoJ antitrust probe pose headline risk for generic companies like Mylan (MYL) and Teva (TEVA).
Generic Stocks Feel Pricing Heat, 1st Charges Filed in DoJ Antitrust Probe
by Arpita Dutt
Key generic drugmakers including Teva (TEVA) saw their shares slip on news that the first charges have been filed in the investigation related to generic drug pricing.
Here's Why Teva Pharmaceutical's (TEVA) Stock Is Down Today
by Ryan McQueeney
Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.